Results 61 to 70 of about 106,723 (263)

HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Children with SCD have elevated stroke risk, correlated with cerebral blood flow velocity (CBFV). HOPE Kids 2 was a phase 3, multicenter, double‐blind, placebo‐controlled trial evaluating the effect of voxelotor on CBFV. Participants aged 2 to < 15 years with SCD (HbSS/HbSβ0) and conditional CBFV (170 to < 200 cm/s) were randomized 1:1 to ...
Halima Bello‐Manga   +58 more
wiley   +1 more source

All‐Printed Multilayers and Blends of Poly(dioxythiophene) Derivatives Patterned into Flexible Electrochromic Displays

open access: yesMacromolecular Materials and Engineering, 2023
Low‐cost, flexible and thin display technology is becoming an interesting field of research as it can accompany the wide range of sensors being developed.
Robert Brooke   +5 more
doaj   +1 more source

3.2.1 A Study of Systems Engineering Effectiveness: Building a Business Case for SE [PDF]

open access: yesINCOSE International Symposium, 2011
AbstractUnderstanding the value of Systems Engineering (SE) is necessary to justify a project's investment in SE resources and activities. To identify the value of SE, the Systems Engineering Effectiveness Committee (SEEC) of the National Defense Industrial Association (NDIA), in collaboration with the Software Engineering Institute (SEI), developed ...
openaire   +1 more source

Morphological and morphometric aspects of the equine aortic valve: New insights for comparative studies in mammals

open access: yesThe Anatomical Record, EarlyView.
Abstract New data on the equine aortic valve obtained using advanced techniques is especially important given the greater availability of animal models for translational research. Here we characterized the morphological and morphometric aspects of the equine aortic valve from 60 healthy hearts collected at equine abattoirs.
Vitor Pires Pereira   +3 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease   +20 more
wiley   +1 more source

Plasma Proteome Reflects Tissue Damage and Clinical Manifestations in Patients With Inflammatory Myopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins.
Yue‐Bei Luo   +23 more
wiley   +1 more source

Airports—Energy and Sustainability Perspectives

open access: yesEnergies
This study explored the role of airports in the aviation sector from both energy and sustainability perspectives, highlighting their potential contribution to reducing the sector’s carbon emissions.
Musadag El Zein   +2 more
doaj   +1 more source

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐07261271 in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim There is an unmet need for more effective therapies in inflammatory bowel disease (IBD). A single drug that blocks multiple distinct pathogenic pathways may offer therapeutic benefit superior to current monotherapies. PF‐07261271, a bispecific antibody targeting both the p40 subunit of interleukin‐12/23 and tumour necrosis factor‐like cytokine 1A ...
Srividya Neelakantan   +11 more
wiley   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen   +13 more
wiley   +1 more source

Engineering heterologous core promoters to optimize the SES expression system for Pichia pastoris

open access: yesSynthetic and Systems Biotechnology
Synthetic biology has revolutionized microbial production by broadening the range of substrates, products, and host organisms. Pichia pastoris, a pivotal system for industrial enzyme production and biopharmaceuticals, encounters limitations in production capacity and transcriptional regulation, which impede its wider application.
Bo Sun   +10 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy